Search

Bismuth subsalicylate

Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. … [A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort.

Vimseltinib

[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

Atrasentan

[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

Narsoplimab

[A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

Seladelpar

[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Tasonermin

It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

DL-alpha-Tocopherol

Tilbroquinol

Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].

Hexachlorophene

A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms.